Please use this identifier to cite or link to this item:
Exportar a:
Full metadata record
DC FieldValueLanguage
dc.coverage.temporal9 (1350)es
dc.creatorMarín-Palma, Damariz-
dc.creatorCastro, Gustavo A.-
dc.creatorCardona-Arias, Jaiberth A.-
dc.creatorUrcuqui-Inchima, Silvio-
dc.creatorHernandez, Juan C.-
dc.description.abstractIntroduction: High-density lipoproteins (HDL) are responsible for the efflux and transport of cholesterol from peripheral tissues to the liver. In addition, HDL can modulate various immunological mechanisms, including the inflammatory response. Inflammasomes are multiprotein complexes that have been reported to be activated during human immunodeficiency virus type 1 (HIV-1) infection, thus contributing to immune hyperactivation, which is the main pathogenic mechanism of HIV-1 progression. However, the relationship between HDL and inflammasomes in the context of HIV-1 infection is unclear. Therefore, this research aims to explore the association between HDL and the components of the inflammatory response during HIV-1 infection. Methodology: A cross-sectional study, including 36 HIV-1-infected individuals without antiretroviral treatment and 36 healthy controls matched by sex and age, was conducted. Viral load, CD4+ T-cell counts, serum HDL, and C-reactive protein (CRP) were quantified. Serum cytokine levels, including IL-1β, IL-6, and IL-18, were assessed by ELISA. The inflammasome-related genes in peripheral blood mononuclear cells were determined by quantitative real-time PCR. Results: HIV-1-infected individuals showed a significant decrease in HDL levels, particularly those subjects with higher viral load and lower CD4+ T-cell counts. Moreover, upregulation of inflammasome-related genes (NLRP3, AIM2, ASC, IL-1β, and IL-18) was observed, notably in those HIV-1-infected individuals with higher viral loads (above 5,000 copies/mL). Serum levels of IL-6 and CRP were also elevated in HIV-1-infected individuals. Significant negative correlations between HDL and the mRNA of NLRP3, AIM2, ASC, IL-1β, and IL-18, as well as viral load and CRP were observed in HIV-1-infected individuals. Likewise, a significant positive correlation between HDL and CD4+ T-cell counts was found. Conclusion: In summary, our results indicate that HDL might modulate the expression of several key components of the inflammasomes during HIV-1 infection, suggesting a novel role of HDL in modifying the inflammatory state and consequently, the progression of HIV-1
dc.publisherUniversidad Cooperativa de Colombia, Facultad de Ciencias de la Salud, Programa de Medicina, Medellín y Envigado, Colombia, 00000es
dc.relation.ispartofFrontiers in Immunologyes
dc.subjecthigh-density lipoproteinses
dc.titleLower High-Density Lipoproteins Levels During Human Immunodeficiency Virus Type 1 Infection Are Associated With Increased Inflammatory Markers and Disease Progressiones
dc.identifier.bibliographicCitationMarín-Palma D, Castro GA, Cardona-Arias JA, Urcuqui-Inchima S and Hernandez JC (2018) Lower High-Density Lipoproteins Levels During Human Immunodeficiency Virus Type 1 Infection Are Associated With Increased Inflammatory Markers and Disease Progression. Front. Immunol. 9:1350. Recuperado de:es
dc.source.bibliographicCitation1. Salemi M. The intra-host evolutionary and population dynamics of human immunodeficiency virus type 1: a phylogenetic perspective. Infect Dis Rep (2013) 5(Suppl 1):e3. doi:10.4081/idr.2013.s1.e3es
dc.source.bibliographicCitation2. UNAIDS. Fact sheet – latest statistics on the status of the AIDS epidemic 2016. Available from: (Accessed: December 20, 2017).es
dc.source.bibliographicCitation3. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med (2006) 12(3):289–95. doi:10.1038/nm1380es
dc.source.bibliographicCitation4. Boasso A, Shearer GM. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol (2008) 126(3):235–42. doi:10.1016/j. clim.2007.08.015es
dc.source.bibliographicCitation5. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 17(13):1881–8. doi:10.1097/01. aids.0000076311.76477.6es
dc.source.bibliographicCitation6. Thea DM, Porat R, Nagimbi K, Baangi M, St Louis ME, Kaplan G, et al. Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1. Ann Intern Med (1996) 124(8):757–62. doi:10.7326/ 0003-4819-124-8-199604150-00009es
dc.source.bibliographicCitation7. Grunfeld C, Kotler DP, Shigenaga JK, Doerrler W, Tierney A, Wang J, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med (1991) 90(2):154–62. doi:10.1016/0002-9343(91)80154-Ees
dc.source.bibliographicCitation8. Espindola MS, Lima LJ, Soares LS, Cacemiro MC, Zambuzi FA, de Souza Gomes M, et al. Dysregulated immune activation in second-line HAART HIV+ patients is similar to that of untreated patients. PLoS One (2015) 10(12):e0145261. doi:10.1371/journal.pone.0145261es
dc.source.bibliographicCitation9. Ahmad R, Sindhu ST, Toma E, Morisset R, Ahmad A. Elevated levels of circulating interleukin-18 in human immunodeficiency virus-infected individuals: role of peripheral blood mononuclear cells and implications for AIDS pathogenesis. J Virol (2002) 76(24):12448–56. doi:10.1128/ JVI.76.24.12448-12456.2002es
dc.source.bibliographicCitation10. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 201(12):1788–95. doi:10.1086/652749es
dc.source.bibliographicCitation11. Granowitz EV, Saget BM, Wang MZ, Dinarello CA, Skolnik PR. Interleukin 1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin 1 receptor antagonist and tumor necrosis factor binding protein type 1. Mol Med (1995) 1(6):667–
dc.source.bibliographicCitation12. Shapiro L, Puren AJ, Barton HA, Novick D, Peskind RL, Shenkar R, et al. Interleukin 18 stimulates HIV type 1 in monocytic cells. Proc Natl Acad Sci U S A (1998) 95(21):12550–5. doi:10.1073/pnas.95.21.12550es
dc.source.bibliographicCitation13. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol (2006) 7(2):131–7. doi:10.1038/ni1303es
dc.source.bibliographicCitation14. Antonucci JM, St Gelais C, Wu L. The dynamic interplay between HIV-1, SAMHD1, and the innate antiviral response. Front Immunol (2017) 8:1541. doi:10.3389/fimmu.2017.01541es
dc.source.bibliographicCitation15. Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci (2014) 1319:82–95. doi:10.1111/nyas.12458es
dc.source.bibliographicCitation16. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol (2013) 13(6):397–411. doi:10.1038/nri3452es
dc.source.bibliographicCitation17. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol (2016) 16(7):407–20. doi:10.1038/nri.2016.58es
dc.source.bibliographicCitation18. Hernandez J, Sirois C, Latz E. “Activation and regulation of the NLRP3 inflammasome” inflammasomes. In: Couillin I, Pétrilli V, Martinon F, editors. The Inflammasomes. Progress in Inflammation Research. Basel: Springer (2011). p. 197–208es
dc.source.bibliographicCitation19. Hernandez JC, Latz E, Urcuqui-Inchima S. HIV-1 induces the first signal to activate the NLRP3 inflammasome in monocyte-derived macrophages. Intervirology (2014) 57(1):36–42. doi:10.1159/000353902es
dc.source.bibliographicCitation20. Feria MG, Taborda NA, Hernandez JC, Rugeles MT. HIV replication is associated to inflammasomes activation, IL-1beta, IL-18 and caspase-1 expression in GALT and peripheral blood. PLoS One (2018) 13(4):e0192845. doi:10.1371/ journal.pone.0192845es
dc.source.bibliographicCitation21. Pontillo A, Silva LT, Oshiro TM, Finazzo C, Crovella S, Duarte AJ. HIV-1 induces NALP3-inflammasome expression and interleukin-1beta secretion in dendritic cells from healthy individuals but not from HIV-positive patients. AIDS (2012) 26(1):11–8. doi:10.1097/QAD.0b013e32834d697fes
dc.source.bibliographicCitation22. Feingold KR, Grunfeld C. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, et al., editors. Introduction to Lipids and Lipoproteins. South Dartmouth, MA: Endotext (2000).es
dc.source.bibliographicCitation23. Marín-Palma D, Taborda N, Urucuqui-Inchima S, Hernandez JC. Inflamación y respuesta inmune innata: Participación de las lipoproteínas de alta densidad. Iatreia (2017) 30(4):423–35. doi:10.17533/udea.iatreia.v30n4a06es
dc.source.bibliographicCitation24. Asztalos BF, de la Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, Rothblat GH. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res (2005) 46(10):2246–53. doi:10.1194/jlr.M500187-JLR200es
dc.source.bibliographicCitation25. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caves
dc.source.bibliographicCitation26. Kameda T, Ohkawa R, Yano K, Usami Y, Miyazaki A, Matsuda K, et al. Effects of myeloperoxidase-induced oxidation on antiatherogenic functions of high-density lipoprotein. J Lipids (2015) 2015:592594. doi:10.1155/2015/ 592594es
dc.source.bibliographicCitation27. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem (2001) 276(37):34480–5. doi:10.1074/jbc.M103782200es
dc.source.bibliographicCitation28. Henning MF, Herlax V, Bakas L. Contribution of the C-terminal end of apolipoprotein AI to neutralization of lipopolysaccharide endotoxic effect. Innate Immun (2011) 17(3):327–37. doi:10.1177/1753425910370709es
dc.source.bibliographicCitation29. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol (1995) 15(11):1987–94. doi:10.1161/ 01.ATV.15.11.1987es
dc.source.bibliographicCitation30. Zhu X, Owen JS, Wilson MD, Li H, Griffiths GL, Thomas MJ, et al. Macrophage ABCA1 reduces MyD88-dependent toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J Lipid Res (2010) 51(11):3196–206. doi:10.1194/jlr.M006486es
dc.source.bibliographicCitation31. De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, et al. Highdensity lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol (2014) 15(2): 152–60. doi:10.1038/ni.2784es
dc.source.bibliographicCitation32. Thacker SG, Zarzour A, Chen Y, Alcicek MS, Freeman LA, Sviridov DO, et al. High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation. Immunology (2016) 149(3):306–19. doi:10.1111/imm.12638es
dc.source.bibliographicCitation33. Zheng F, Xing S, Gong Z, Mu W, Xing Q. Silence of NLRP3 suppresses atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice. Mediators Inflamm (2014) 2014:507208. doi:10.1155/2014/507208es
dc.source.bibliographicCitation34. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med (1977) 62(5):707–14. doi:10.1016/0002-9343(77) 90874-9es
dc.source.bibliographicCitation34. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med (1977) 62(5):707–14. doi:10.1016/0002-9343(77) 90874-9 and anti-atherosclerotic enzymes. Nat Struct Mol Biol (2004) 11(5):412–9. doi:10.1038/nsmb767es
dc.source.bibliographicCitation36. Bounafaa A, Berrougui H, Ghalim N, Nasser B, Bagri A, Moujahid A, et al. Association between paraoxonase 1 (PON1) polymorphisms and the risk of acute coronary syndrome in a north African population. PLoS One (2015) 10(8):e0133719. doi:10.1371/journal.pone.0133719es
dc.source.bibliographicCitation37. Estrada V, Martinez-Larrad MT, Gonzalez-Sanchez JL, de Villar NG, Zabena C, Fernandez C, et al. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism (2006) 55(7):940–5. doi:10.1016/j.metabol.2006.02.024es
dc.source.bibliographicCitation38. Marbaniang IP, Kadam D, Suman R, Gupte N, Salvi S, Patil S, et al. Cardiovascular risk in an HIV-infected population in India. Heart Asia (2017) 9(2):e010893. doi:10.1136/heartasia-2017-010893es
dc.source.bibliographicCitation39. Ross AC, Rizk N, O’Riordan MA, Dogra V, El-Bejjani D, Storer N, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis (2009) 49(7):1119–27. doi:10.1086/ 605578es
dc.source.bibliographicCitation40. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years – United States. MMWR Recomm Rep (2008;) 57(RR–10):1–
dc.source.bibliographicCitation41. Gomez DM, Urcuqui-Inchima S, Hernandez JC. Silica nanoparticles induce NLRP3 inflammasome activation in human primary immune cells. Innate Immun (2017) 23(8):697–708. doi:10.1177/1753425917738331es
dc.source.bibliographicCitation42. Hernandez JC, St Laurent G III, Urcuqui-Inchima S. HIV-1-exposed seronegative individuals show alteration in TLR expression and pro-inflammatory cytokine production ex vivo: An innate immune quiescence status? Immunol Res (2016) 64(1):280–90. doi:10.1007/s12026-015-8748-8es
dc.source.bibliographicCitation43. Hernandez JC, Giraldo DM, Paul S, Urcuqui-Inchima S. Involvement of neutrophil hyporesponse and the role of Toll-like receptors in human immunodeficiency virus 1 protection. PLoS One (2015) 10(3):e0119844. doi:10.1371/ journal.pone.0119844es
dc.source.bibliographicCitation44. Godsland IF, Wynn V, Crook D, Miller NE. Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions. Am Heart J (1987) 114(6):1467–503. doi:10.1016/0002-8703(87)90552-7es
dc.source.bibliographicCitation45. Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr (1989) 2(2):114–
dc.source.bibliographicCitation46. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med (2013) 173(8):614–22. doi:10.1001/jamainternmed.2013.3728es
dc.source.bibliographicCitation47. Borges AH, Silverberg MJ, Wentworth D, Grulich AE, Fatkenheuer G, Mitsuyasu R, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS (2013) 27(9):1433–41. doi:10.1097/QAD.0b013e32835f6b0ces
dc.source.bibliographicCitation48. Gupta SK, Kitch D, Tierney C, Melbourne K, Ha B, McComsey GA, et al. Markers of renal disease and function are associated with systemic inflammation in HIV infection. HIV Med (2015) 16(10):591–8. doi:10.1111/hiv.12268es
dc.source.bibliographicCitation49. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA (2003) 289(22):2978–82. doi:10.1001/jama.289.22.2978es
dc.source.bibliographicCitation50. Anastos K, Lu D, Shi Q, Tien PC, Kaplan RC, Hessol NA, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr (2007) 45(1):34–42. doi:10.1097/ QAI.0b013e318042d5fees
dc.source.bibliographicCitation51. Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, Downing R, et al. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr (2008) 47(3):304–11. doi:10.1097/ QAI.0b013e31815e7453es
dc.source.bibliographicCitation52. Rose H, Woolley I, Hoy J, Dart A, Bryant B, Mijch A, et al. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism (2006) 55(1):90–5. doi:10.1016/j.metabol.2005.07.012es
dc.source.bibliographicCitation53. Bernal E, Masia M, Padilla S, Gutierrez F. High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition. AIDS Patient Care STDS (2008) 22(7):569–75. doi:10.1089/apc.2007.0186es
dc.source.bibliographicCitation54. Shen Y, Wang J, Wang Z, Qi T, Song W, Tang Y, et al. Prevalence of dyslipidemia among antiretroviral-naive HIV-infected individuals in China. Medicine (2015) 94(48):e2201. doi:10.1097/MD.0000000000002201es
dc.source.bibliographicCitation55. Feingold KR, Soued M, Serio MK, Moser AH, Dinarello CA, Grunfeld C. Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology (1989) 125(1):267–74. doi:10.1210/endo-125-1-267es
dc.source.bibliographicCitation56. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr (1994) 7(11):1149–
dc.source.bibliographicCitation57. Li XA, Titlow WB, Jackson BA, Giltiay N, Nikolova-Karakashian M, Uittenbogaard A, et al. High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide synthase in a ceramidedependent manner. J Biol Chem (2002) 277(13):11058–63. doi:10.1074/jbc. M110985200es
dc.source.bibliographicCitation58. Pontillo A, Oshiro TM, Girardelli M, Kamada AJ, Crovella S, Duarte AJ. Polymorphisms in inflammasome’ genes and susceptibility to HIV-1 infection. J Acquir Immune Defic Syndr (2012) 59(2):121–5. doi:10.1097/QAI. 0b013e3182392ebees
dc.source.bibliographicCitation59. Pontillo A, Carvalho MS, Kamada AJ, Moura R, Schindler HC, Duarte AJ, et al. Susceptibility to Mycobacterium tuberculosis infection in HIV-positive patients is associated with CARD8 genetic variant. J Acquir Immune Defic Syndr (2013) 63(2):147–51. doi:10.1097/QAI.0b013e31828f93bbes
dc.source.bibliographicCitation60. Chivero ET, Guo ML, Periyasamy P, Liao K, Callen SE, Buch S. HIV-1 Tat primes and activates microglial NLRP3 inflammasome-mediated neuroinflammation. J Neurosci (2017) 37(13):3599–609. doi:10.1523/JNEUROSCI.3045- 16.2017es
dc.source.bibliographicCitation61. Haque S, Lan X, Wen H, Lederman R, Chawla A, Attia M, et al. HIV promotes NLRP3 inflammasome complex activation in murine HIV-associated nephropathy. Am J Pathol (2016) 186(2):347–58. doi:10.1016/j.ajpath.2015. 10.002es
dc.source.bibliographicCitation62. Mamik MK, Hui E, Branton WG, McKenzie BA, Chisholm J, Cohen EA, et al. HIV-1 viral protein R activates NLRP3 inflammasome in microglia: implications for HIV-1 associated neuroinflammation. J Neuroimmune Pharmacol (2016) 12(2):233–48. doi:10.1007/s11481-016-9708-3es
dc.source.bibliographicCitation63. Guo H, Gao J, Taxman DJ, Ting JP, Su L. HIV-1 infection induces interleukin1beta production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes. J Biol Chem (2014) 289(31):21716–26. doi:10.1074/jbc.M114.566620es
dc.source.bibliographicCitation64. Kreuzer KA, Dayer JM, Rockstroh JK, Sauerbruch T, Spengler U. The IL-1 system in HIV infection: peripheral concentrations of IL-1beta, IL-1 receptor antagonist and soluble IL-1 receptor type II. Clin Exp Immunol (1997) 109(1):54–8. doi:10.1046/j.1365-2249.1997.4181315.xes
dc.source.bibliographicCitation65. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 5(10):e203. doi:10.1371/journal. pmed.0050203es
dc.source.bibliographicCitation66. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res (2004) 45(7): 1169–96. doi:10.1194/jlr.R300019-JLR200es
dc.source.bibliographicCitation67. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature (2010) 464(7293):1357–61. doi:10.1038/ nature08938es
dc.source.bibliographicCitation68. Schroder K, Tschopp J. The inflammasomes. Cell (2010) 140(6):821–32. doi:10.1016/j.cell.2010.01.040es
dc.source.bibliographicCitation69. Lamkanfi M, Dixit VM. Manipulation of host cell death pathways during microbial infections. Cell Host Microbe (2010) 8(1):44–54. doi:10.1016/j. chom.2010.06.007es
dc.source.bibliographicCitation70. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol (2009) 7(2):99–109. doi:10.1038/nrmicro2070es
dc.source.bibliographicCitation71. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature (2014) 505(7484):509–14. doi:10.1038/nature12940es
dc.source.bibliographicCitation72. Rangaswamy KS. Correlation between High-density Lipoprotein Cholesterol Level and CD4 Cell Count in HIV Patients on NNRTI-Based ART Regimen at Tertiary Care Hospital in Mysuru. Int J Sci Stud (2017) 5(3):150–4. doi:10.17354/ijss/2017/286es
dc.source.bibliographicCitation73. Jiang Y, Wang M, Huang K, Zhang Z, Shao N, Zhang Y, et al. Oxidized low-density lipoprotein induces secretion of interleukin-1beta by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation. Biochem Biophys Res Commun (2012) 425(2):121–6. doi:10.1016/j. bbrc.2012.07.011es
dc.source.bibliographicCitation74. Samstad EO, Niyonzima N, Nymo S, Aune MH, Ryan L, Bakke SS, et al. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J Immunol (2014) 192(6):2837–45. doi:10.4049/ jimmunol.1302484es
dc.source.bibliographicCitation75. Niyonzima N, Samstad EO, Aune MH, Ryan L, Bakke SS, Rokstad AM, et al. Reconstituted high-density lipoprotein attenuates cholesterol crystal-induced inflammatory responses by reducing complement activation. J Immunol (2015) 195(1):257–64. doi:10.4049/jimmunol.1403044es
dc.source.bibliographicCitation76. Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Krankel N, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of toll-like receptor-2. Immunity (2013) 38(4):754–68. doi:10.1016/j. immuni.2013.02.009es
dc.source.bibliographicCitation77. Duro M, Sarmento-Castro R, Almeida C, Medeiros R, Rebelo I. Lipid profile changes by high activity anti-retroviral therapy. Clin Biochem (2013) 46(9):740–4. doi:10.1016/j.clinbiochem.2012.12.017es
dc.source.bibliographicCitation78. Zangerle R, Widner B, Quirchmair G, Neurauter G, Sarcletti M, Fuchs D. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin Immunol (2002) 104(3):242–7. doi:10.1006/clim. 2002.5231es
Appears in Collections:Medicina

Files in This Item:
File Description SizeFormat 
HDL VIH Frontiers 2018.pdf1.23 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.